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One-step nucleic acid amplification (OSNA) is an intraoperative technique with a high sensitivity and specificity for sentinel node
assessment. The aim of this study was to assess the impact of OSNA on micrometastases detection rates and use of adjuvant
chemotherapy. A retrospective review of patients with sentinel node micrometastases over a five-year period was carried out and a
comparison ofmicrometastases detection usingOSNAandH&E techniqueswasmade.Out of 1285 patientswhounderwent sentinel
node (SLN) biopsy, 76 patients had micrometastases. Using H&E staining, 36 patients were detected with SLN micrometastases
(9/year) in contrast to 40 patients in the OSNA year (40/year) (𝑝 < 0.0001), demonstrating a fourfold increase with the use of
OSNA. In the OSNA group, there was also a proportional increase in Grade III, triple-negative, ER-negative, and HER-2-positive
tumours being diagnosed withmicrometastases. Also on interactive PREDICT tool, the number of patients with a predicted 10-year
survival benefit of more than 3% with adjuvant chemotherapy increased from 52 to 70 percent. OSNA has resulted in an increased
detection rate of micrometastases especially in patients with aggressive tumour biology.This increased the number of patients who
had a predicted survival benefit from adjuvant chemotherapy.
1. Introduction
Axillary lymph node status at the time of initial diagnosis is
one of the most important prognostic indicators for breast
cancer. The goal of axillary node clearance (ANC) is to pro-
vide accurate staging information and local control of the dis-
ease. However, it has many potential complications including
lymphedema, seroma, shoulder dysfunction, and paraesthe-
sia. Sentinel lymph node (SLN) biopsy has replaced ANC due
to its lower morbidity and equivalent long-term prognosis [1,
2]. Several methods of SLN assessment exist ranging from the
conventional gold-standard haematoxylin and eosin (H&E)
histopathological examination with or without immunohis-
tochemistry staining tomore rapid intraoperative assessment
techniques that offer the ability to make a decision about
axillary surgery at the time of the primary procedure.
The one-step nucleic acid amplification (OSNA) is an
intraoperative technique which detects and quantifies the
presence of cytokeratin 19 (CK-19) mRNA in a lymph node
by polymerase chain reaction (PCR) [3]. This technology
has been validated by several authors [4–13] and endorsed
by National Institute of Clinical Excellence in August 2013
[14]. There are suggestions that OSNA has resulted in
increased detection of metastases, especially micrometas-
tases, in comparison to traditionalmethods [15–17].However,
themanagement of axilla with sentinel nodemicrometastases
has changed over the last few years. ANC was routinely
carried out in patients with sentinel node micrometastases
but studies have shown no survival advantage [18]. There
is also evidence to suggest that micrometastases in itself
should not be an indication for systemic treatment [19]. Since
the introduction of OSNA in our institution in November
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2012, we have observed a trend towards increased detection
of SLN micrometastases with a potential impact on adju-
vant treatment decisions. Therefore we assessed the rates of
micrometastases diagnosed by OSNA and the use of adjuvant
chemotherapy.
2. Materials and Methods
This study was carried out in a University Hospital which
deals with around 600 breast cancer referrals per annum. All
patients who underwent SLN biopsy between January 2009
and December 2013 were included. Retrospective data on
demographic details, presentation, type of surgery, number
and status of lymph nodes, and histological tumour details
was collected and analysed.
SLN biopsy was performed using a conventional dual
technique of intradermal technetium 99 radioactive nanocol-
loid injection and subdermal blue dye injection (patent blue).
Before November 2012, histological evaluation was carried
out using standard H&E staining. All sentinel nodes were
sent as formalin fixed specimen to the lab. The nodes were
the sectioned in 2.0mm slices before embedding them in
paraffin blocks. H&E staining was only carried out in the
sentinel node assessment. In November 2012, OSNA was
adopted in our institution and underwent a 3-month period
of internal validation where half the SLN was examined by
OSNA and the other half was sent for traditional assessment.
We adopted the standard CK-19 mRNA copy count to
stratify the size of metastasis where mRNA copy count of
<250 copies/𝜇L, 250–5000 copies/𝜇L, and >5000 copies/𝜇L is
considered as negative, micrometastases, and macrometas-
tases, respectively [3].
The mean sentinel node retrieval rate was two, both in
pre- and post-OSNA group. ANC was performed if one or
more SLNs were positive for macrometastases. The man-
agement of micrometastases changed during the course of
use of OSNA; in the beginning of the study period the
surgeonsweremore inclined to carry outANC ifmicrometas-
tases were found but in the latter part, a more judicious
approach was adopted based on the change in attitude
towards ANC. The data was collated and analysed using
Microsoft Excel (Microsoft Corporation, Redmond, USA).
𝑝 values were calculated using the Chi-square test (𝜒2).
Ten-year survival benefit with adjuvant chemotherapy was
retrospectively calculated using PREDICT online, version 1.2
[20], where micrometastases were considered node negative
for calculation purposes.
3. Results
In the 5-year study period between January 2009 andDecem-
ber 2013, a total of 1285 SLN biopsies were performed out
of which 76 patients had SLN micrometastases (6%). The
demographic details and tumour characteristics are given in
Table 1.
In the pre-OSNA period of the study (January 2009–
November 2012), 36 cases with micrometastases were
detected with a consistent detection rate of 9 cases per
annum. There was a significant increase in detection of
Table 1: Demographic and tumour characteristics.
Pre-OSNA Post-OSNA
(2009–2012) (2013)
Number of patients (n/%) 36 (47.4%) 40 (52.6%)
Age (range) 57 (39–74) 60 (32–76)
Screen detected 12 (33.3%) 21 (52.5%)
Tumour size (mm) 25.9 18.3
Tumour grade (n/%)
Grade 1 5 (14%) 2 (5%)
Grade 2 18 (50%) 21 (52.5%)
Grade 3 13 (36%) 17 (42.5%)
ER receptor (n/%)
Positive 31 (86%) 28 (70%)
Negative 5 (14%) 11 (27.5%)
Borderline 0 1 (2.5%)
HER-2 receptor (n/%)
Positive 6 (16.6%) 6 (15%)
Negative 30 (83.3%) 34 (85%)
Triple negative (n/%) 6 (16.6%) 8 (20%)
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Figure 1: Distribution of detected micrometastases over the study
period (𝑝 < 0.0001).
micrometastaseswith the introduction ofOSNA (𝑝 < 0.0001).
This is despite a steady caseload of cancers per annum
(Figure 1).
After the introduction of OSNA, a fourfold increase in
Grade III tumourswithmicrometastases was noted. A similar
trend was noted in triple-negative cases and the number of
HER-2-positive cases increased from 2/annum to 6 in the
OSNA year (Figure 2) and ER-negative cases increased from
14.1% to 25% (Table 1).
In the pre-OSNA period 24 symptomatic (66.7%) and
12 screen-detected (33.3%) patients were found to have
micrometastases. In the post-OSNA period, however 19
symptomatic (47.5%) and 21 screen-detected (52.5%) patients
had micrometastases detected (NS).
During this study period, 34 out of 76 patients (44.7%)
over the study period underwent ANC on the basis of
micrometastases detection. In the pre-OSNA period, 26
patients (72.2%) underwent ANC and 8 patients (30.7%)were
found to have further positive nonsentinel axillary nodes. In
contrast, out of 8 patients (20%) who underwent ANC in the
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Figure 2: Distribution of micrometastases in aggressive tumours
during the study period.
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Figure 3: Adjuvant chemotherapy before and after the introduction
of OSNA.
OSNA period, only one (12.5%) was found to have further
positive nonsentinel nodes (NS).
Twenty-one patients (58.3%) in the pre-OSNAperiod and
23 patients (57.5%) in the OSNA period received adjuvant
chemotherapy (Figure 3).The tumour characteristics of these
patients are given in Table 2. Eight patients in the pre-
OSNA group and 2 patients in the post-OSNA group with
aggressive tumour biology (Grade III, triple-negative, or
HER-2-positive) did not receive chemotherapy due to factors
such as age, comorbidities, or patients’ choice.
Using the PREDICT tool, a survival advantage from
chemotherapy in both of these groups was calculated. In
the chemotherapy group, 11 patients (52%) in the pre-OSNA
period and 16 patients (70%) in the OSNA period had a
predicted 10-year survival benefit of >3% with systemic treat-
ment.
4. Discussion
Our study has demonstrated a fourfold increase in micro-
metastases detection rate with the introduction of OSNA. In
the last year of the study, when OSNA was adopted, almost
as many micrometastases were detected as in the previous
Table 2: Tumour characteristics of patients who underwent adju-
vant chemotherapy.
Pre-OSNA Post-OSNA
(2009–2012) (2013)
Number of patients (n/%) 21 23
Age (range) 54 (39–69) 53 (32–74)
Screen detected 6 (28.5%) 6 (26%)
Tumour size (mm) 26.5 21.8
Tumour grade (n/%)
Grade 1 1 (5%) 0 (0%)
Grade 2 12 (57%) 7 (30%)
Grade 3 8 (38%) 16 (70%)
ER receptor (n/%)
Positive 17 (80.9%) 14 (60.8%)
Negative 4 (19.1%) 8 (38%)
Borderline 0 1 (1.2%)
HER-2 receptor (n/%)
Positive 2 (9.5%) 6 (25.1%)
Negative 19 (90.5%) 17 (73.9%)
Triple negative (n/%) 4 (19%) 6 (26%)
Predicted 10-year survival
benefit with chemotherapy >3% 11 (52%) 16 (70%)
four years. The reason for this discrepancy is not entirely
clear. A possible explanation could be that the whole node
is used for OSNA analysis rather than only sections. It could
also be due to human factors and varying interpretation
of histological specimens and technique of node processing
itself. Turner and his colleagues highlighted interobserver
discrepancies when they demonstrated that the interpreta-
tions of six experienced breast pathologists varied in 23.8%
when asked to review 56 electronic images of small-volume
disease [21]. Cserni et al. showed that different interpretations
of the TNM definitions could cause variations in the clas-
sification of small-volume disease and therefore impact the
staging of the disease [22]. Conventional histopathology may
underestimate the size of the metastasis leading to possible
false-negative results. Intensive examination of the node is
essential to pick up low-volume deposits [23] with sec-
tion thickness of about 200–250𝜇m needed to demonstrate
micrometastases reliably [24]. This can increase pathology
workload enormously and cannot be done intraoperatively.
We believe that OSNA analysis of the node in its entirety
detects deposits that would have otherwise been missed by
the pathologist. In our study, the 4-fold increase in the
detection of micrometastases could have been due to the
same reason. These views were corroborated in a study by
Osako et al. who whilst finding no difference in detecting
macrometastases between OSNA and frozen section found
that OSNA detected significantly more micrometastases [15].
A plausible explanation for the increased detection rates with
OSNA is false-positive results due to potential contamination
with benign epithelial cells [25]. Another possibility is that
considering the sensitivity of the technique, OSNA could be
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picking up Isolated Tumour Cells and interpreting them as
micrometastases. In this context, a recent meta-analysis has
commented on the potential high false positives with the
technique of OSNA [17].
In our study, we observed that the micrometastases
detection rate in the screening population rose considerably
after the introduction of OSNA (33.3% to 52.5%). It is
possible that screening patients with early disease could
have had smaller SLN deposits that would have otherwise
beenmissed on histopathology. Unsurprisingly the screening
population in our cohort had smaller average tumour size
than the symptomatic population (19.6mm versus 26.3mm)
as reported in literature [26–28].
Further nonsentinel node positivity following ANC in
patients with micrometastases was higher in the pre-OSNA
group (30.7% versus 12.5%). This finding is possibly a reflec-
tion of the sensitivity of OSNA or the potential for slightly
increased false-positive results with its use. However, the
numbers in our series are too low to make any practical
interpretation.
The prognostic significance and therapeutic implications
of SLN micrometastases remain a matter of great debate.
With the use of OSNA, the information provided is difficult
to apply in clinical setting. Studies have shown that SLN
micrometastases are not associated with worse prognosis
than node-negative patients [29]. Therefore, chemotherapy
should not be recommended to all patients particularly the
ones who do not have aggressive tumour characteristics as
the potential benefit from chemotherapy is small and side-
effects are considerable. In our study, there was an increase
in the number of OSNA detected micrometastases in HER-2-
positive cases as well as ER-negative cases which can only be
explained by the ability of OSNA to detect micrometastases
in patients withmore aggressive biology.With the increase in
the rate of micrometastases, there was also an increase in the
number of patients who had a predicted survival advantage
with chemotherapy in OSNA period.
In our practice, PREDICT online is routinely used to
assess long-term prognosis in order to decide about adjuvant
treatment options. It takes into account the mode of presen-
tation, size, and grade of tumour along with the estrogen
and HER-2 receptor status. The predictive accuracy of this
online tool has been validated by many studies published in
literature [30, 31]. Patientswith a predicted survival advantage
of >3% are offered adjuvant chemotherapy. On the PREDICT
score, 11% patients in the pre-OSNA period had a 10-year
survival advantage of >3% in contrast to 16% patients in the
post-OSNA group. This could be due to the proportionally
higher number of patients withGrade III, triple-negative, and
HER-2-positive tumours in the OSNA period. It could be
argued that the increase in themicrometastases detection rate
during theOSNAperiodmay be due to the biological features
of the tumour with the sensitive OSNA technique picking up
axillary disease in aggressive variants of cancer.
A recent systematic review on the clinical effectiveness
of OSNA concluded that a lack of histological information
such as the location of metastatic foci and the morphological
features with intraoperative analysis reduces the diagnostic
accuracy. This has also raised the question if the cost
reduction with intraoperative testing is worth the reduction
in diagnostic accuracy and potentially inferior long-term
health outcomes for patients [32]. An interesting finding in
our study was a fourfold increase in detection of micrometas-
tases in aggressive tumour variants with the use of OSNA.
These micrometastases were probably missed in the pre-
OSNA era and in the context of having poor prognostic
tumour are likely to be true metastatic deposits. The increase
in micrometastases detection rate in the OSNA year reflects
the sensitivity of this technique.
5. Conclusion
OSNA has resulted in increased rate of detection of
micrometastases. There was also an increased detection rate
of micrometastases particularly in patients with aggressive
tumour characteristics and in the use of adjuvant chemother-
apy, but this was more likely to be due to the tumour biology.
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